The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | The implications of SARS-CoV-2 infection in patients undergoing stem cell transplantation
Meera Mohan, MD, MS, FACP, Medical College of Wisconsin, Milwaukee, WI, discusses key findings from a study which used the National COVID Cohort Collaborative (N3C) database to analyze the possible implications of SARS-CoV-2 infection in patients undergoing stem cell transplantation for hematologic malignancies. Dr Mohan believes that, where possible, reconsidering the timing of transplant for patients recovering from a SARS-CoV-2 infection is crucial. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Research Funding; BMS/Celgene: Research Funding; Takeda: Research Funding; Novartis: Research Funding.
